Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 22, 2011
Valuing EQ-5D using time trade-off in FranceJulie Chevalier, Gérard de Pouvourville
Melanoma Research|January 30, 2008
The economic burden of melanoma in France: assessing healthcare use in a hospital settingJulie Chevalier, Julia Bonastre, Marie-Françoise Avril
Cerebrovascular Diseases (Basel, Switzerland)|April 26, 2013
Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillationJulie Chevalier, Maurice Giroud, Gérard de Pouvourville
Plos One|March 18, 2016
Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal PerspectiveJulie Chevalier, Catherine Chamoux, Florence Hammès, et al.
Archives of Cardiovascular Diseases|June 29, 2014
Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspectiveJulie Chevalier, Olivier Delaitre, Florence Hammès, et al.
Marine Environmental Research|October 11, 2011
PAH biomarkers in common eelpout (Zoarces viviparus) from Danish watersZhanna M Tairova, Jakob Strand, Julie Chevalier, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|December 26, 2012
A comparison of the scaling properties of the English, Spanish, French, and Chinese EQ-5D descriptive systemsNan Luo, Minghui Li, Julie Chevalier, et al.
Environmental Toxicology and Chemistry|March 12, 2015
Exploration of Daphnia behavioral effect profiles induced by a broad range of toxicants with different modes of actionJulie Chevalier, Elodie Harscoët, Merlin Keller, et al.
International Journal of Technology Assessment in Health Care|March 25, 2022
A Review of Overall Survival Extrapolations of Immune-Checkpoint Inhibitors Used in Health Technology Assessments by the French Health AuthoritiesValentine Grumberg, Stéphane Roze, Julie Chevalier, et al.
Health Policy (Amsterdam, Netherlands)|December 10, 2013
Access to innovation: is there a difference in the use of expensive anticancer drugs between French hospitals?Julia Bonastre, Julie Chevalier, Chantal Van der Laan, et al.
Pageof 3